Diagnostic Ventures

Rapid testing saves lives.

Diagnostic Ventures is building the most comprehensive sepsis diagnostics platform, targeting pathogen identification within 20 minutes.

350,000 U.S. adults die from sepsis annually, and 80% of sepsis deaths could be prevented with rapid diagnosis and appropriate treatment.¹

Helping physicians make faster, better-informed treatment decisions.

Get involved

Scroll to explore

Building a better tomorrow

About us

Born out of a $5.4M NIH research grant at Brigham Young University, Diagnostic Ventures is a proud Utah-native startup on a mission to transform sepsis care. We are engineering a diagnostic solution that replaces traditional blood cultures, eliminating critical wait times and empowering providers to save lives.

This product is currently under development and is not yet FDA-approved or available for commercial sale.

Our story →

Our solution

Direct bacterial identification from whole blood.

Clarity ID™ is designed to isolate pathogens directly from whole blood, bypassing traditional culture processes. It brings together microfluidics, Raman spectroscopy, and machine learning to rapidly identify bacteria.

Meet Clarity ID™

Clarity ID diagnostic instrument in a laboratory

The human cost of sepsis

A global emergency measured in lives.

50Msepsis infections each year²

11Msepsis deaths each year²

1 in 5deaths worldwide caused by sepsis³

References

Zanotti-Cavazzoni S. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Yearbook of Critical Care Medicine. 2007;187–188.
Global Sepsis Alliance, 2024.
Rudd et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study, 2020.

Understand the problem →

Move faster with us

Partner with us.

Every minute counts when diagnosing sepsis. We are pioneering the world’s fastest comprehensive pathogen identification system to eliminate the wait for blood cultures and save lives. Reach out to learn more about our technology, clinical timeline, or partnership opportunities.